News

Partner companies' news

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis

Acorn Management Partners, Administrator
April 2022 — 423 views PCSA

SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors

Acorn Management Partners, Administrator
April 2022 — 461 views SABS

Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update

Acorn Management Partners, Administrator
April 2022 — 427 views PCSA

SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results

Acorn Management Partners, Administrator
April 2022 — 419 views SABS

Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST

Acorn Management Partners, Administrator
March 2022 — 420 views PCSA

Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference

Acorn Management Partners, Administrator
March 2022 — 438 views PCSA

About us

Helping America invest in you:

Connecting your company stock with professional market participants.

One call at a time

Stay updated :

Participate on our social stream.

Our Blogs

Tags

Archives